Sai Zhang, PhD, has been named a 2025 awardee of Target ALS's Drug Discovery Consortia program, a strategic initiative to advance novel therapeutic targets for amyotrophic lateral sclerosis toward clinical testing.
Zhang serves as co-lead investigator on a multi-institutional consortium developing antisense oligonucleotide therapy to safely target CCDC146, a protein that plays a critical role in protecting nerve cells affected by ALS. The team includes researchers from University of Sheffield, SynOligo, University of Southern California, and Genentech.